Similar articles for PMID: 10994731

Year	Number of Results
1976	1
1980	1
1984	1
1989	1
1990	2
1991	2
1992	7
1993	17
1994	27
1995	24
1996	24
1997	29
1998	27
1999	18
2000	31
2001	30
2002	16
2003	16
2004	12
2005	18
2006	13
2007	13
2008	13
2009	7
2010	6
2011	6
2012	13
2013	4
2014	6
2015	5
2016	6
2017	7
2018	3
2019	2
2021	2
2022	0

1

Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.

Janson ET, Westlin JE, Ohrvall U, Oberg K, Lukinius A. Janson ET, et al. J Nucl Med. 2000 Sep;41(9):1514-8. J Nucl Med. 2000. PMID: 10994731 Free article.

2

Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide.

Andersson P, Forssell-Aronsson E, Johanson V, Wängberg B, Nilsson O, Fjälling M, Ahlman H. Andersson P, et al. J Nucl Med. 1996 Dec;37(12):2002-6. J Nucl Med. 1996. PMID: 8970523 Free article.

3

Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide.

Westlin JE, Janson ET, Arnberg H, Ahlström H, Oberg K, Nilsson S. Westlin JE, et al. Acta Oncol. 1993;32(7-8):783-6. doi: 10.3109/02841869309096136. Acta Oncol. 1993. PMID: 8305227

4

In vivo cellular distribution and endocytosis of the somatostatin receptor-ligand complex.

Lukinius A, Ohrvall U, Westlin JE, Oberg K, Tiensuu Janson E. Lukinius A, et al. Acta Oncol. 1999;38(3):383-7. doi: 10.1080/028418699431483. Acta Oncol. 1999. PMID: 10380832

5

64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.

Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, Lewis JS, McCarthy DW. Anderson CJ, et al. J Nucl Med. 2001 Feb;42(2):213-21. J Nucl Med. 2001. PMID: 11216519 Free article.

6

Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.

Kwekkeboom DJ, Kooij PP, Bakker WH, Mäcke HR, Krenning EP. Kwekkeboom DJ, et al. J Nucl Med. 1999 May;40(5):762-7. J Nucl Med. 1999. PMID: 10319747 Free article.

7

Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.

Hofland LJ, Lamberts SW, van Hagen PM, Reubi JC, Schaeffer J, Waaijers M, van Koetsveld PM, Srinivasan A, Krenning EP, Breeman WA. Hofland LJ, et al. J Nucl Med. 2003 Aug;44(8):1315-21. J Nucl Med. 2003. PMID: 12902423 Free article.

8

Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide.

Forssell-Aronsson E, Fjälling M, Nilsson O, Tisell LE, Wängberg B, Ahlman H. Forssell-Aronsson E, et al. J Nucl Med. 1995 Jan;36(1):7-12. J Nucl Med. 1995. PMID: 7799086 Free article.

9

Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers.

Kälkner KM, Janson ET, Nilsson S, Carlsson S, Oberg K, Westlin JE. Kälkner KM, et al. Cancer Res. 1995 Dec 1;55(23 Suppl):5801s-5804s. Cancer Res. 1995. PMID: 7493349 Free article.

10

Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability.

Haldemann AR, Rösler H, Barth A, Waser B, Geiger L, Godoy N, Markwalder RV, Seiler RW, Sulzer M, Reubi JC. Haldemann AR, et al. J Nucl Med. 1995 Mar;36(3):403-10. J Nucl Med. 1995. PMID: 7884502 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed